Role of serum lactate dehydrogenase levels in evaluating efficacy of interventional therapy for hepatocellular carcinoma

摘要

Objective The aim of the study was to investigate the role of serum lactate dehydrogenase(LDH)levels in evaluating the efficacy of transcatheter arterial chemoembolization(TACE)for primary liver cancer.Methods A total of 52 patients with liver cancer admitted in our hospital(Huangzhou District People’s Hospital,Huanggang,China)from June 2015 to December 2017 were selected and divided into control group(LDH of≤450 U/L,n=26)and observation group(LDH of>450 U/L,n=26),based on the pretreatment level of LDH.Based on the changes in serum LDH levels before and after treatment,patients were classified into two groups:LDH increased group(22 cases)and LDH decreased group(30 cases).The relationship between LDH levels and efficacy of TACE treatment was analyzed in the four groups retrospectively.Results No significant difference was seen in the clinical characteristics(gender,median age,performance status Eastern Cooperative Oncology Group,and staging system)between the control and observation groups.The efficacy rate in the control group was 57.7%,whereas that in the observation group was 42.3%(P>0.05).The 1-year survival rate in the observation group was 53.8%and that in the control group was 84.6%(P<0.05).Conclusion Serum LDH levels may be of clinical value in evaluating the efficacy of TACE in patients with hepatocellular carcinoma.